Any doctor in NSW can prescribe a cannabis medicine if they believe it is an appropriate treatment option and they have the relevant authorities.Learn more
The Therapeutic Goods Administration (TGA) has updated the medicinal cannabis section of their website, including adding new resources on the access pathways for cannabis medicines.
On 21 September 2020, the Therapeutic Goods Administration registered Epidyolex® on the Australian Register of Therapeutic Goods (ARTG).
In February 2020, recruitment commenced for the CARE NSW trial (Cannabinoids for Symptom Control in Advanced Cancer, an Open Label Prospective Clinical Trial in NSW).
The Therapeutic Goods Administration (TGA) today introduced an online system to enable medical practitioners to submit Special Access Scheme (SAS) applications and notifications electronically.